A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications during the quarter.
Kaigene Inc. has entered into an exclusive global licensing agreement with Celltrion Inc. for two of Kaigene’s nonclinical-stage assets, KG-006 and KG-002. Kaigene’s pipeline leverages its technology to selectively degrade pathogenic antibodies that mainly exacerbate various autoimmune diseases.
In atopic dermatitis (AD), the itch-scratch cycle is tied to skin inflammation exacerbation that accelerates the progression of the disease, thus impacting the patient’s quality of life, where IL-31 is crucial to induce skin itching. Helixon Ltd. has developed a bispecific antibody targeting both IL-31 and OX40L, HXN-1022, for the treatment of AD.
Oncolytic viruses are a potential therapeutic approach that uses viruses to selectively infect and kill cancer cells. In a new publication in Cell Reports Medicine, researchers from Heinrich-Heine-Universität Düsseldorf and Abalos Therapeutics GmbH show that tumor-tropic mutations in lymphocytic choriomeningitis virus (LCMV) enhance selective replication in cancer cells.
Psychiatry has struggled to enter the precision medicine era. But through a mix of innovations and bootstrapping, progress is coming to the field. Scientists are working on improving diagnoses by investigating potential biomarkers and collection methods.
Insmed Inc. has described cathepsin C (dipeptidyl peptidase I; DPP-1) inhibitors reported to be useful for the treatment of cancer, liver injury, osteoarthritis, heart failure, inflammatory bowel disease, rheumatoid arthritis, bronchiectasis and chronic obstructive pulmonary disease, among others.
Guangdong Yinzhu Pharmaceutical Technology Co. Ltd. and Guangzhou Yinzhu Biomedical Technology Co. Ltd. have divulged triazole compounds reported to be useful for the treatment of cancer, psoriasis, rheumatoid arthritis and inflammatory bowel disease.
Sunrise Oncology (Hong Kong) Ltd. has synthesized molecular glues acting as GTPase KRAS (and/or its mutant)/RAF proto-oncogene serine/RAF1 interaction inhibitors reported to be useful for the treatment of cancer.
RSS
